New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight The FDA’s recent approval of OZEMPIC ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

Sotagliflozin significantly reduces heart attacks and strokes in high-risk patients with diabetes and kidney disease, offering a new treatment option for cardiovascular protection. Sotagliflozin, a re ...

Lupin and its alliance partner Natco received clearance from the FDA for bosentan tablets for oral suspension, 32 mg, which ...

Over the two-year study, Zhang's team followed the medical records of 64,705 veterans with diabetes and chronic kidney ...

Travere Therapeutics shares rose sharply in early trading Tuesday after the biopharmaceutical company said it plans to seek expanded Food and Drug Administration approval of its kidney-disease drug ...

Millions of Americans take proton pump inhibitors (PPIs) like Prilosec, Nexium, and Prevacid to manage acid reflux, heartburn, and gastroesophageal reflux disease (GERD).

Lupin has received tentative approval from the Food and Drug Administration for darunavir, cobicistat, emtricitabine, and ...

Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...

Sotagliflozin, a drug for diabetes and kidney disease, offers significant protection against heart attacks and strokes by ...

The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...